Training Grant in Cancer Biology

此修订后的申请寻求在癌症生物学培训计划（T32 CB）的11-15年的续期， 马里兰州巴尔的摩大学（UMB）的格林鲍姆综合癌症中心（UMGCCC）。我们 每年请求支持4名博士前学生和4名博士后研究员。为了丰富T32 CB， UMGCCC将提供额外的博士后职位，特别是代表性不足的少数民族，提高总数 T32 CB博士后插槽为5/年。T32 CB专注于多学科癌症生物学研究培训， 翻译使命。我们的目标是：1）提供实验室和临床之间的双向翻译 通过研究和教学课程，2）在当代基础教育的关键领域提供出色的培训， 和转化癌症研究和3）招募和保留一个强大的专家教师导师组，使 学员的网络化生产力。这些目标是在一个精心设计的计划中实现的， 确保针对特定癌症的成分的个性化灵活性。这36位导师是从 UMGCCC教师基于他们发表的科学成就，研究资金的跟踪记录， 转化癌症研究和指导学员的经验。Predoc组件，包括PhD 和MD/博士学者，建立和加强研究生课程的癌症生物学轨道的培训 生命科学（GPILS）博士后部分为博士、医学博士和医学博士/博士提供研究培训 博士后，包括外科住院医师或血液学/医学研究期间的医生-科学家 肿瘤学奖学金培训。一个长期的T32 CB的优势是预科学生的整合，博士后博士- 科学家和医生科学家谁参加并排在期刊俱乐部（JC），在研究进展 (RIP)研讨会和实验室的工作台上。T32 CB拥有强大的机构支持和 优秀的研究培训环境，翻译和基础之间的合作关系 癌症研究教师和获得尖端技术，促进专门的研究活动。 在项目评估的基础上，提出了几个创新点，包括扩展 癌症基因组学/生物信息学培训和接触癌症生物工程。专业发展 机会为所有受训人员今后的职业生涯做好准备。T32 CB的培训记录非常 强：受训人员发表了富有成效的文章，并获得了奖项、赠款和研究金。的有效性 我们培养下一代癌症研究人员的使命很高，100%的T32 CB毕业生继续 研究相关的职业。T32 CB利用UMGCCC对癌症差异的强调， 对代表性不足的少数民族的培训率很高（18%）。新的多元化咨询委员会将进一步加强 T32 CB招聘和保留来自不同背景的高素质学员。我们的团队科学 方法，由明星导师指导，使我们有才华的医生和博士科学家创造和贡献 到跨学科的科学，这可能会产生创新的好处，为癌症患者。

This revised application seeks renewal for Years 11-15 of the Training Program in Cancer Biology (T32CB) in the Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Baltimore (UMB). We are requesting support for 4 predoctoral students and 4 postdoctoral fellows each year. To enrich the T32CB, UMGCCC will provide an additional postdoc position, especially an underrepresented minority, raising the total T32CB postdoc slots to 5/year. T32CB focuses on multidisciplinary cancer biology research training with a translational mission. Our objectives are: 1) to provide productive bidirectional translation between lab and clinic through research and didactic sessions, 2) to provide outstanding training in critical areas of contemporary basic and translational cancer research and 3) to recruit and retain a strong group of expert faculty mentors to enable networked productivity of trainees. These objectives are accomplished in a carefully structured program that ensures individual flexibility with specific cancer-focused components. The 36 mentors were selected from UMGCCC faculty based on their published scientific achievements, track record of research funding, interest in translational cancer research and experience in mentoring trainees. The predoc component, which includes PhD and MD/PhD scholars, builds from and enhances training in the Cancer Biology Track of the Graduate Program in Life Sciences (GPILS). The postdoc component provides research training for PhD, MD and MD/PhD postdocs, including physician-scientists during the research years of Surgery residency or Hematology/Medical Oncology fellowship training. A longstanding T32CB strength is integration of predoc students, postdoc PhD- scientists, and physician-scientists who participate side-by-side in journal clubs (JC), in research-in-progress (RIP) seminars and at the bench in laboratories. The T32CB enjoys strong institutional support and an outstanding research training environment, with collaborative relationships between translational and basic cancer research faculty and access to cutting-edge technologies that facilitate specialized research activities. Based on program evaluations, several innovations are proposed in this renewal application, including expanded training in cancer genomics/bioinformatics and exposure to cancer bioengineering. Professional development opportunities prepare all trainees for the next stages in their careers. The T32CB training record is extremely strong: trainees publish productively and are recipients of awards, grants and fellowships. The effectiveness of our mission to train the next generation of cancer researchers is high, with 100% of T32CB graduates continuing in research-related careers. The T32CB leverages UMGCCC’s emphasis on cancer disparities to attract and train underrepresented minorities at a high rate (18%). A new Diversity Advisory Committee will further enhance T32CB recruitment and retention of highly qualified trainees from diverse backgrounds. Our team science approach, guided by stellar mentors, enables our talented physician- and PhD-scientists to create and contribute to transdisciplinary science that is likely to yield innovative benefits for cancer patients.